Adverse effects cause Varenicline discontinuation: a meta-analysis
Drovandi, Aaron D., Chen, Carla C., and Glass, Beverley D. (2016) Adverse effects cause Varenicline discontinuation: a meta-analysis. Current Drug Safety, 11 (1). pp. 78-85.
![[img]](https://researchonline.jcu.edu.au/style/images/fileicons/application_pdf.png) |
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
Purpose: Varenicline, the newest agent marketed for smoking cessation is regarded as effective in providing prolonged smoking abstinence. However, its adverse effect profile may cause discontinuation, potentially reducing smoking abstinence rates, thus requiring an examination of the frequency and impact of adverse effects on discontinuation.
Methods: We sought only Randomised Controlled Trials (RCTs) evaluating the effectiveness and safety of varenicline on humans, with a follow-up period of at least three months and an average Fagerstrom Test for Nicotine Dependence (FTND) score at least 5 (moderate dependence) for both the active and placebo groups. PubMed, Medscape, JCU One Search, ClinicalTrials.gov (U.S.), and the Cochrane Collaboration from January 2006 to January 2015 were searched. Fixed and random effects models were run to determine relationships between adverse effects and premature discontinuation from varenicline.
Results: 12 RCTs were included, involving 5 459 patients, with those receiving varenicline found to be nearly twice as likely (Odds ratio (OR) = 1.82 [1.47; 2.26]) to experience adverse effects compared to those patients on a placebo. The active group experienced nearly a 1.5 times higher (OR = 1.47 [1.19; 1.81]) rate of discontinuation. Nausea, insomnia, and headache are the most commonly reported adverse effects, with ORs of 4.40 [3.80; 5.11], 1.75 [1.48; 2.08], and 1.20 [1.02; 1.41] respectively.
Conclusion: Adverse effects experienced during varenicline treatment appear to be associated with higher discontinuation, which are linked to lowered smoking cessation rates, suggesting a need for strategies to minimise the impacts of adverse effects, to better ensure adherence.
| Item ID: | 45496 |
|---|---|
| Item Type: | Article (Research - C1) |
| ISSN: | 1574-8863 |
| Keywords: | adherence, adverse effects, nicotine addiction, smoking cessation, varenicline |
| Date Deposited: | 20 Jul 2016 07:42 |
| FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3214 Pharmacology and pharmaceutical sciences > 321402 Clinical pharmacology and therapeutics @ 75% 52 PSYCHOLOGY > 5202 Biological psychology > 520205 Psychopharmacology @ 15% 32 BIOMEDICAL AND CLINICAL SCIENCES > 3214 Pharmacology and pharmaceutical sciences > 321499 Pharmacology and pharmaceutical sciences not elsewhere classified @ 10% |
| SEO Codes: | 92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920414 Substance Abuse @ 50% 92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920408 Health Status (e.g. Indicators of Well-Being) @ 50% |
| Downloads: |
Total: 2 |
| More Statistics |
Actions (Repository Staff Only)
 |
Item Control Page |